Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced endometrial carcinoma.

Alejandro Falcon Gonzalez,Luis Paz-Ares,Gregory M. Cote,Santiago Ponce-Aix,Julia Martinez,Elizabeth Jimenez Aguilar,Elena Brehcist,Rafael Núñez,Jesus R Fernandez,Sonia Extremera,Carmen Kahatt,Ali Zeaiter,Inmaculada Sanchez-Simon

Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced endometrial carcinoma.

2021

Alejandro Falcon Gonzalez
Luis Paz-Ares
Gregory M. Cote
Santiago Ponce-Aix
Julia Martinez
Elizabeth Jimenez Aguilar
Elena Brehcist
Rafael Núñez
Jesus R Fernandez
Sonia Extremera
Carmen Kahatt
Ali Zeaiter
Inmaculada Sanchez-Simon

5586Background: LUR is a new agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical synergism/additivity in c...

Keywords:

Cancer research
Tumor microenvironment
in patient
Medicine
Carcinoma
Lurbinectedin
antitumor activity
Transcription (biology)
Irinotecan

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations